TLR7 and cancer: Also, resiquimod is another TLR7//TLR8 agonist that is ten times more potent to induce Th1 immune response than imiquimod and can be considered as a potent vaccine adjuvant (due to a high increase in the antigenicity of the cancer antigen) against cancers, including melanoma with the vaccine candidate NY-ESO-1 protein, emulsified Montanide (Sabado et al., 2015[170]; Thomsen et al., 2004[207]).